Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

Emmanuel Antonarakis, A. J. Armstrong

Research output: Contribution to journalArticle

Abstract

Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

Original languageEnglish (US)
Pages (from-to)206-218
Number of pages13
JournalProstate Cancer and Prostatic Diseases
Volume14
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

Castration
Prostatic Neoplasms
Therapeutic Human Experimentation
Therapeutics
Epigenomics
Cell Survival
Clinical Trials
Bone and Bones
Survival

Keywords

  • castrate-resistant prostate cancer
  • clinical trials
  • drug development
  • novel therapies

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. / Antonarakis, Emmanuel; Armstrong, A. J.

In: Prostate Cancer and Prostatic Diseases, Vol. 14, No. 3, 09.2011, p. 206-218.

Research output: Contribution to journalArticle

@article{9bf1b7b9891f4f6fa4ef65d1e353d5d6,
title = "Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer",
abstract = "Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.",
keywords = "castrate-resistant prostate cancer, clinical trials, drug development, novel therapies",
author = "Emmanuel Antonarakis and Armstrong, {A. J.}",
year = "2011",
month = "9",
doi = "10.1038/pcan.2011.24",
language = "English (US)",
volume = "14",
pages = "206--218",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

AU - Antonarakis, Emmanuel

AU - Armstrong, A. J.

PY - 2011/9

Y1 - 2011/9

N2 - Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

AB - Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

KW - castrate-resistant prostate cancer

KW - clinical trials

KW - drug development

KW - novel therapies

UR - http://www.scopus.com/inward/record.url?scp=80054749674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054749674&partnerID=8YFLogxK

U2 - 10.1038/pcan.2011.24

DO - 10.1038/pcan.2011.24

M3 - Article

VL - 14

SP - 206

EP - 218

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 3

ER -